We are registered as an independent intermediary for medicines with the Dutch Ministry of Health
How to buy Perjeta:
You can order Perjeta (pertuzumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
HER2-positive breast cancer
Mode of Action
HER2/neu receptor antagonist (immunotherapy)
EMA approved (EU); FDA approved (USA); TGA approved (AUS)
30 mg / mL
Who is pertuzumab for?
Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer . Use in combination with trastuzumab and docetaxel (other cancer medicines) for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease . Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer .
Complete information about Perjeta (pertuzumab) dosage and administration can be found here . The standard dosage is:
Initial dose: 840 mg administered as a 60-minute intravenous infusion
Following infusions: 420 mg administered as a 30 to 60-minute intravenous infusion every 3 weeks.
Patients with metastatic breast cancer should be treated with pertuzumab and trastuzumab until disease progression or unmanageable toxicity. Patients in neoadjuvant treatment of breast cancer should be administered pertuzumab every 3 weeks for 3 to 6 cycles before surgery. Consult your treating doctor for personalised dosing.
What is pertuzumab and how does it work?
Perjeta (pertuzumab) is a HER2/neu receptor antagonist indicated for the treatment of HER2 positive breast cancer in metastatic patients or as neoadjuvant therapy . Pertuzumab is a monoclonal antibody that has been designed to recognise and attach to HER2, a protein found on the surface of HER2-positive cancer cells. By attaching to HER2, pertuzumab stops HER2 producing signals that cause the cancer cells to grow. It also activates cells of the immune system, which then kill the cancer cells .
for HER2 positive breast cancer in metastatic patients or as neoadjuvant therapy. The approvals of pertuzumab for metastatic breast cancer were based on a multicentre, randomised, double-blind, placebo-controlled phase III clinical trial (CLEOPATRA - WO20698) which included 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer. Patients received either placebo, trastuzumab and docetaxel or pertuzumab, trastuzumab and docetaxel. The addition of pertuzumab to the treatment resulted in an extension of the median progression-free survival (PFS) by over 6 months (18.5 months vs 12.4 months) . The median overall survival (OS) was 56.5 months in patients who took pertuzumab compared to 40.8 in patients who didn’t. The difference in overall response rate (ORR) was 10.8 % in favour of pertuzumab (80.2 % vs. 69.3 %) with 5.5 % complete responses (vs. 4.2 %) . The approvals of pertuzumab as neoadjuvant treatment of breast cancer was based on two studies. The first, a phase II, multicentre, multinational randomized controlled trial (NEOSPHERE - WO20697) which involved 417 patients with newly diagnosed, early, inflammatory or locally advanced HER2-positive breast cancer who had not received prior trastuzumab, chemotherapy or radiotherapy. Patients were randomised to receive one of the following neoadjuvant regimens for 4 cycles prior to surgery:
trastuzumab plus docetaxel
Perjeta (pertuzumab) plus trastuzumab and docetaxel
The pathological complete response (pCR) — defined as the absence of residual invasive disease in the breast and in the armpit lymph nodes at the completion of the neoadjuvant treatment  — was 39.3 % [95 % CI: 30, 49.2] in the group that took pertuzumab in combination with trastuzumab and docetaxel which was 2 to almost 4 times higher than the other combinations . The second study (TRYPHAENA - BO22280) a multicentre, randomised phase II clinical trial, involved 225 adult female patients with HER2-positive locally advanced, operable, or inflammatory breast cancer who had not received prior trastuzumab, chemotherapy or radiotherapy. Patients were randomly allocated to receive 1 of 3 neoadjuvant regimens prior to surgery as follows:
3 cycles of FEC (5-Fluorouracil, epirubicin, and cyclophosphamide) followed by 3 cycles of docetaxel all in combination with Perjeta (pertuzumab) and trastuzumab,
3 cycles of FEC alone followed by 3 cycles of docetaxel and trastuzumab in combination with Perjeta (pertuzumab)
6 cycles of docetaxel, carboplatin, and trastuzumab in combination with Perjeta (pertuzumab).
The highest pCR rates were achieved in the last of the three groups, with a pCR rate of 66.2% [95 % CI: 54.6; 76.6] vs 61.6 % [95 % CI: 49.5; 72.8] and 57.3% [95 % CI: 45.4; 68.7] in the first and second group, respectively .
Buyer There is a 6% tax on medicines + 21% tax on shipping for EU individuals
Shipping Cost Estimate
*Once you provide us with the exact shipping address, the actual price may vary.
Send this price estimate to your email address
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions